Brief: Shenzhen Neptunus Interlong Bio-Technique Says Bought 51% Stake In Beijing Zhongxin Pharma
22/04/2021 16:11
April 22 (Reuters) - Shenzhen Neptunus Interlong
Bio-technique Co Ltd 8329.HK :
* ACQUISITION OF 51% EQUITY INTEREST IN BEIJING ZHONGXIN
PHARMACEUTICAL CO FOR RMB76.5 MILLION
Source text for Eikon: ID:nHKS5KsrDH
Further company coverage: 8329.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Neptunus Interlong Bio-technique
See all newsBrief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million